Selenium, Genetic Variation, and Prostate Cancer Risk: Epidemiology Reflects Back on Selenium and Vitamin E Cancer Prevention Trial
|
|
- Marcia Matthews
- 5 years ago
- Views:
Transcription
1 VOLUME 27 NUMBER 22 AUGUST JOURNAL OF CLINICAL ONCOLOGY E D I T O R I A L Selenium, Genetic Variation, and Prostate Risk: Epidemiology Reflects Back on Selenium and Vitamin E Prevention Trial Elizabeth A. Platz, Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health; James Buchanan Brady Urological Institute; and Sidney Kimmel Comprehensive Center, Johns Hopkins Medical Institutions, Baltimore, MD Scott M. Lippman, Divisions of Medicine and Prevention and Population Sciences, The University of Texas M. D. Anderson Center, Houston, TX The randomized, controlled Selenium and Vitamin E Prevention Trial (SELECT) 1 found that selenium supplementation did not decrease the risk of prostate cancer, which contradicted a secondary finding from the Nutritional Prevention of (NPC) Study. 2 In the wake of SELECT, we expect that many groups will report results from epidemiologic studies on selenium and prostate cancer, some of which may illuminate reasons for SELECT s null results. One such effort is reported in this issue of Journal of Clinical Oncology by Chan et al, 3 who conducted a cross-sectional epidemiologic study of plasma selenium, an SOD2 variant, and aggressive prostate cancer in men diagnosed with clinically localized or locally advanced prostate cancer and who provided a blood specimen. They observed an unexpected positive association between plasma selenium and aggressive disease. As expected, an SOD2 variant, a substitution of alanine for valine at amino acid 16 in the antioxidant enzyme manganese superoxide dismutase, was not statistically significantly associated with aggressive disease, although the relative risks (RRs) for one or two alanine alleles were above 1.0. Two patterns emerged in the analysis of the joint association of plasma selenium and SOD2: men with low selenium and two alanine alleles had a higher risk of aggressive disease (compared with low selenium and none or one alanine alleles); high selenium seemingly protected men with two alanine alleles; and men with high selenium and none or one alanine allele had a higher risk of aggressive disease (compared with low selenium and none or one alanine allele). In light of these findings, Chan et al 3 commented that their data indicate caution against broad use of selenium supplementation for men with prostate cancer and that complete interpretation of results from SELECT may depend on assessment of SOD2 genotype in trial participants. Before discussing the broader context (related observational studies, the NPC study, and SELECT) and implications of this study, we will discuss a design feature that complicates drawing etiologic inferences and thus implications for selenium supplementation from the Chan et al study. 3 They estimated the prevalence of aggressive disease in a cohort of men with prostate cancer, making the denominator for risk calculation men with prostate cancer. Etiologic research on aggressive prostate cancer typically estimates risk of aggressive disease in a cohort of men who do not have a diagnosis of prostate cancer at baseline, making at-risk men without prostate cancer the denominator. Table 1 illustrates several hypothetical scenarios (a subset of all possible scenarios) that could explain the higher risk of aggressive prostate cancer found by Chan et al in men with higher plasma selenium. Columns 4 to 6 involve a typical cohort of at-risk men. The cohort of cancer patients (aggressive and nonaggressive) involved in column 7 is derived from the at-risk cohort and reflects the design of Chan et al. Although all are hypothetical, the data and assumptions in Table 1 are consistent with the epidemiologic literature on nutrients and genetic variants and are not out of line with the data of Chan et al (the same can be said of the hypothetical data and assumptions in Table 2, which is discussed below). Scenario D is a plausible scenario in which the increased RR of aggressive disease (1.25) in a design similar to that of the study by Chan et al would be misleading because the true RR of aggressive disease is 0.75, as illustrated by the more informative typical cohort design. Scenarios A to D are all plausible but unknowable because of this study s design. Differences in implication make it absolutely critical to discern the correct scenario behind the Chan et al results. The implication of hypothetical scenarios A and C caution against taking a selenium supplement is diametrically opposed to that of B and D a recommendation for taking a selenium supplement. The typical cohort design for etiologic research, using at-risk individuals, enables correct implications that are not derivable from a design using cancer patients at baseline. The design of the study by Chan et al is frequently used in clinical studies of potential biomarker associations or correlations with cancer aggressiveness, where inferences are unambiguous (barring other sources of error). This design also sometimes is used for etiologic research, but investigators should be alert to the etiologic ambiguity it raises for interpreting a positive or inverse association between an exposure and aggressive disease. Previously published studies in at-risk men may help in drawing inferences from the Chan et al 3 findings on the main effects of selenium and SOD2 and their joint effects, which are even more challenging to interpret with a cohort of only cancer patients. Regarding associations between circulating selenium and overall prostate cancer, Journal of Clinical Oncology, Vol 27, No 22 (August 1), 2009: pp by American Society of Clinical Oncology 3569 DOI: /JCO ; published online ahead of print at on June 15, 2009
2 Platz and Lippman Table 1. Hypothetical Scenarios Involving an At-Risk Cohort of Men That May Explain the Apparent Positive Association Made by Chan et al 3 Between Higher Circulating Selenium Level and Aggressive Prostate Scenario Hypothetical True Direction of Association Between Selenium and Prostate Aggressive Nonaggressive Typical Cohort Design for Etiologic Research: Denominator Is At-Risk Men Without Prostate at Baseline RR of Total Prostate RR of Aggressive Prostate RR of Nonaggressive Prostate Chan et al 3 Design: Denominator Is Men With Prostate RR of Aggressive Prostate A 1 Null ( /1,000)/ ( /1,000) 1.13 B Null 2 ( /1,000)/ ( /1,000) 0.85 C 1 2 ( /1,000)/ ( /1,000) 1.00 D 2 22 ( /1,000)/ ( /1,000) 0.60 (53.3/1,000)/(40/1,000) 1.33 (60/1,000)/(60/1,000) 1.00 (53.3/ ) / (40/ ) 1.18 (40/1,000)/(40/1,000) 1.00 (45/1,000)/(60/1,000) 0.75 (40/ )/ (40/ ) 1.18 (53.3/1,000)/(40/1,000) 1.33 (45/1,000)/(60/1,000) 0.75 (53.3/ )/ (40/ ) 1.36 (30/1,000)/(40/1,000) 0.75 (30/1,000)/(60/1,000) 0.50 (30/ )/ (40/ ) 1.25 Abbreviation: RR, relative risk. 1 and 2 signify an increase or decrease in risk of 1.33 or 0.75 (these RRs are equidistant from the null on the natural logarithm scale), respectively in the high-selenium group. 22 signifies a decrease in risk of 0.5 in the high-selenium group. The cohort in these columns consists of 2,000 at-risk men, half of whom are in the high-selenium group. In the low-selenium group, 100 men develop prostate cancer, 40% of which is aggressive disease. The cohort in this column consists of the prostate cancer cases that are diagnosed in the cohort in. Denominator is all prostate cancer cases in the high-selenium group. Denominator is all prostate cancer cases in the low-selenium group. most large studies found no association, 4-7 whether the study involved populations with low or high selenium exposure or with or without routine prostate-specific antigen (PSA) screening (one small study did find an inverse association 8 ). Regarding associations between selenium levels and aggressive disease, a study of selenium content in toenails 9 and some other studies 4,6 reported inverse, albeit nonlinear, associations and other studies reported no association. 5,6 Regarding associations between selenium and nonaggressive disease, 4-6 only the Physician s Health Study (PHS) 4 found an association, which was an inverse association with nonaggressive disease diagnosed before but not since the PSA era began. If selenium is not associated with nonaggressive disease in the PSA era, then the Chan et al finding of a positive association for aggressive disease likely is not explained by scenario B, C, or D in Table 1 (suggesting prevention of nonaggressive disease). The worrisome scenario A showing an increased risk of aggressive disease with selenium, however, contradicts the findings of some large studies. 4,6,9 Again, we cannot be certain which scenario is correct because of the etiologic ambiguity resulting from the Chan et al study design. Large studies with a risk-estimation denominator of at-risk men suggest that the SOD2 alanine allele is positively associated with prostate cancer, although so weakly in some studies that the authors concluded no association. 13,14 In studies finding a moderate association, it was present for aggressive and nonaggressive disease 10,12 but possibly was stronger for the former. The Chan et al 3 results are consistent with these results 10,12 ; if the alanine allele is more strongly positively associated with aggressive than nonaggressive disease in a typical, at-risk cohort design, then the RR of aggressive disease would be above 1.0 when using the Chan et al design (Table 2, in which the hypothetical scenario is constructed as are those in Table 1). The PHS and another cohort study with an at-risk denominator for risk estimation 11,13 found a joint association for two alanine alleles plus low selenium with a higher prostate cancer risk (compared with none or one alanine alleles and low selenium), which was more Table 2. Hypothetical Scenario Involving an At-Risk Cohort of Men That May Explain the Apparent Positive Association Made by Chan et al 3 Between the Alanine Allele of SOD2 and Aggressive Prostate Hypothetical True Direction of Association Between the Alanine Allele and Prostate Aggressive Nonaggressive Typical Cohort Design: Denominator Is Men Without Prostate at Baseline RR of Total Prostate RR of Aggressive Prostate RR of Nonaggressive Prostate Chan et al 3 Design: Denominator Is Men With Prostate RR of Aggressive Prostate 11 1 ( /1,000)/ ( /1,000) 1.60 (80/1,000)/(40/1,000) 2.00 (79.8/1,000)/(60/1,000) 1.33 (80/ ) / (40/ ) 1.25 Abbreviation: RR, relative risk. 1signifies an increase in risk of 1.33 in the group with 2 alanine alleles. 11 signifies an increase in risk of 2.0 in the group with 2 alanine alleles. The cohort in these columns consists of 2,000 at-risk men, sampled so that half have two alanine alleles and half have zero alanine alleles. In the group with zero alanine alleles, 100 men develop prostate cancer, 40% of which is aggressive disease. The cohort in this column consists of the prostate cancer cases that are diagnosed in the cohort in. Denominator is all prostate cancer cases in the two alanine-allele group. Denominator is all prostate cancer cases in the zero alanine-allele group by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY
3 Editorial pronounced for aggressive disease in the PHS. 13 In contrast, men with high selenium had a lower risk of prostate cancer irrespective of the number of alanine alleles they carried. 13 This pattern is not unique to selenium, however. An increased risk of aggressive disease was associated with two alanine alleles and low lycopene in the Health Professionals Follow-up Study (HPFS) 14 and with two alanine alleles and low lycopene and low total antioxidants in the PHS. 13 Regarding effects on nonaggressive disease, there was no clear interaction between antioxidant status and SOD2 genotype in the PHS, 13 and it can be inferred that there was no interaction between lycopene and SOD2 genotype or that it possibly was inversely associated in the HPFS. 14 The increased risk of aggressive prostate cancer in men with two alanine alleles and low selenium in the study by Chan et al 3 is compatible with the results from these at-risk denominator studies (paralleling the argument depicted in Table 2). But again, the interaction with SOD2 may not be selenium specific. The only finding in Chan et al 3 that is not compatible with the previous studies of the association between selenium and prostate cancer reviewed here 1,2,4-14 is the overall increased risk of aggressive disease associated with higher circulating selenium, which was driven by men with none or one alanine allele. Possible contributors to this incompatible result were the Chan et al study design and methodologic limitations discussed by the authors (eg, lack of temporality and a small sample size for evaluating joint effects). The study population, however, had a selenium exposure (eg, distribution comparable to that in US adult men 15 ) and outcome (eg, PSA era) similar to those in some of the other observational studies. Serum selenium in the Chan et al study was higher than in the NPC study 16 but lower than in SELECT, 1 and the distribution of stage/grade was likely intermediate between the NPC study (which straddled the pre-psa and PSA era) and SELECT (PSA era, and virtually all patients had T1/T2 and Gleason 3 4 disease). In the NPC study, the inverse association for selenium supplementation was present for both local and advanced disease and was strongest in men with low circulating selenium. 16 The null SELECT result implies no association of selenium supplementation with nonaggressive disease. Baseline selenium level associations with outcome have not been evaluated in SELECT, 1 so it is unknown whether supplementation in this trial may have decreased prostate cancer risk in men with low baseline selenium, as in the NPC study, and concurrently increased the risk of overall or aggressive disease in men with high baseline selenium, as in the Chan et al study. That selenium may have opposing effects at high versus low exposures is plausible. In the NPC study, baseline plasma selenium and total cancer (all sites) risk were directly associated in the selenium supplement arm and possibly inversely associated in the placebo arm. 17 Therefore, what seems to be an anomalous prostate cancer result of Chan et al warrants additional investigation. The findings of Chan et al 3 and others 1,2,4-14 raise questions that may lead to an increased understanding of selenium supplementation in men at risk of prostate cancer. Did selenium supplementation in SELECT reduce the risk of total or high-grade prostate cancer in men with baseline circulating selenium levels as low as in the bottom tertile of the NPC study? Did selenium supplementation in SELECT increase the risk of total or high-grade disease in men with baseline circulating selenium levels as high as in the top quintile of the Chan et al study? If one combined across large observational studies to achieve adequate sample size for phenotype and a wider range between low and high selenium levels, would higher circulating selenium be associated with the risk of prostate cancer that is aggressive or nonaggressive as determined by stage alone, grade alone, both, and both plus PSA level? In SELECT or combined large observational studies, is the selenium effect on (or association with) prostate cancer risk beneficial, detrimental, or null in those groups of men with higher and lower exposure to other antioxidants; higher and lower production or activity of antioxidant enzymes including manganese superoxide dismutase, perhaps as measured by genotype; higher and lower exposure to oxidant sources; and with variously combined exposures to selenium, other antioxidants, antioxidant enzymes, and oxidant sources? Readers should note that the SOD2 interaction with circulating selenium in relation to prostate cancer risk was present for low lycopene and total antioxidants, not just selenium. Furthermore, manganese superoxide dismutase encoded by SOD2 is only one of a large number of antioxidant enzymes. All of these interactions deserve in-depth study. A last question, which probably cannot be resolved by data from epidemiologic studies, is whether lifelong, distant-past, or recent selenium level is critical to supplement effects on prostate cancer risk. None of the large observational studies or trials addressed the role of selenium in preventing prostate cancer recurrence, nor did Chan et al 3 despite their caution against broad use of selenium supplementation for men with prostate cancer. Long-term follow-up of prostate cancer patients characterized for selenium levels before, at, and after diagnosis and treatment will be required to address recurrence. Adjusting for stage and grade at diagnosis will be necessary to determine if selenium predicts recurrence independently of these two prognostic factors. Placing the findings of Chan et al 3 and SELECT in the context of the existing literature does not clarify the role of selenium in prostate cancer etiology. Nevertheless, we offer a couple of working hypotheses. Selenium supplementation does not decrease risk except possibly in selenium-deficient populations. Supplementation possibly increases risk of prostate cancer, especially aggressive disease, in selenium-replete men or men with a particular genotype for antioxidant enzymes. These hypotheses and the questions posed above suggest the need for personalized risk prediction. At present, we do not know enough to determine how much selenium any man or woman should receive from the diet or a supplement. This lack of knowledge supports the common public health recommendation of moderation with respect to supplements for men and women. Furthermore, we should encourage men and women to eat a wide array of foods, maintain normal weight, be physically active, not smoke, and drink in moderation if at all to prevent chronic diseases in general. Unlike the prospect of personalized chemoprevention, this is not new or exciting advice, but it is common sense. AUTHORS DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST The author(s) indicated no potential conflicts of interest. AUTHOR CONTRIBUTIONS Conception and design: Elizabeth A. Platz, Scott M. Lippman Data analysis and interpretation: Elizabeth A. Platz, Scott M. Lippman Manuscript writing: Elizabeth A. Platz, Scott M. Lippman Final approval of manuscript: Elizabeth A. Platz, Scott M. Lippman REFERENCES 1. Lippman SM, Klein EA, Goodman PJ, et al: Effect of selenium and vitamin E on risk of prostate cancer and other cancers: The Selenium and Vitamin E Prevention Trial (SELECT). JAMA 301:39-51, Clark LC, Combs GF Jr, Turnbull BW, et al: Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin: A by American Society of Clinical Oncology 3571
4 Platz and Lippman randomized controlled trial Nutritional Prevention of Study Group. JAMA 276: , Chan JM, Oh WK, Xie W, et al: Plasma selenium, manganese superoxide dismutase, and intermediate- or high-risk prostate cancer. J Clin Oncol 27: , Li H, Stampfer MJ, Giovannucci EL, et al: A prospective study of plasma selenium levels and prostate cancer risk. J Natl Inst 96: , Peters U, Foster CB, Chatterjee N, et al: Serum selenium and risk of prostate cancer: A nested case-control study. Am J Clin Nutr 85: , Allen NE, Appleby PN, Roddam AW, et al: Plasma selenium concentration and prostate cancer risk: Results from the European Prospective Investigation into and Nutrition (EPIC). Am J Clin Nutr 88: , Gill JK, Franke AA, Steven Morris J, et al: Association of selenium, tocopherols, carotenoids, retinol, and 15-isoprostane F(2t) in serum or urine with prostate cancer risk: The multiethnic cohort. Causes Control [epub ahead of print on February 11, 2009] 8. Brooks JD, Metter EJ, Chan DW, et al: Plasma selenium level before diagnosis and the risk of prostate cancer development. J Urol 166: , Yoshizawa K, Willett WC, Morris SJ, et al: A study of prediagnostic selenium level in toenails and the risk of advanced prostate cancer. J Natl Inst 90: , Woodson K, Tangrea JA, Lehman TA, et al: Manganese superoxide dismutase (MnSOD) polymorphism, alpha-tocopherol supplementation and prostate cancer risk in the alpha-tocopherol, beta-carotene cancer prevention study (Finland). Causes Control 14: , Kang D, Lee KM, Park SK, et al: Functional variant of manganese superoxide dismutase (SOD2 V16A) polymorphism is associated with prostate cancer risk in the prostate, lung, colorectal, and ovarian cancer study. Epidemiol Biomarkers Prev 16: , Cooper ML, Adami HO, Gronberg H, et al: Interaction between single nucleotide polymorphisms in selenoprotein P and mitochondrial superoxide dismutase determines prostate cancer risk. Res 68: , Li H, Kantoff PW, Giovannucci E, et al: Manganese superoxide dismutase polymorphism, prediagnostic antioxidant status, and risk of clinical significant prostate cancer. Res 65: , Mikhak B, Hunter DJ, Spiegelman D, et al: Manganese superoxide dismutase (MnSOD) gene polymorphism, interactions with carotenoid levels and prostate cancer risk. Carcinogenesis 29: , Niskar AS, Paschal DC, Kieszak SM, et al: Serum selenium levels in the US population: Third National Health and Nutrition Examination Survey, Biol Trace Elem Res 91:1-10, Clark LC, Dalkin B, Krongrad A, et al: Decreased incidence of prostate cancer with selenium supplementation: Results of a double-blind cancer prevention trial. Br J Urol 81: , Duffield-Lillico AJ, Dalkin BL, Reid ME, et al: Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: An analysis of the complete treatment period of the Nutritional Prevention of Trial. BJU Int 91: , by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY
5 CORRECTIONS Author Correction The October 10, 2010, article by Zhu et al, entitled, Prognostic and Predictive Gene Signature for Adjuvant Chemotherapy in Resected Non Small-Cell Lung (J Clin Oncol 28: , 2010), contained errors. In Figures 2E and 2F, the x-axes were erroneously labeled as Time (months), whereas they should have been labeled Time (years). The authors apologize to the readers for the mistakes. DOI: /JCO Journal Corrections The August 1, 2009, editorial by Platz and Lippman, entitled, Selenium, Genetic Variation, and Prostate Risk: Epidemiology Reflects Back on Selenium and Vitamin E Prevention Trial (J Clin Oncol 27: , 2009), contained an error in the online version. The second author, Scott M. Lippman, was inadvertently omitted from the author list. Journal of Clinical Oncology apologizes to the authors and readers for the mistake. DOI: /JCO The April 1, 2010, article by Feldman et al, entitled, TI-CE High-Dose Chemotherapy for Patients With Previously Treated Germ Cell Tumors: Results and Prognostic Factor Analysis (J Clin Oncol 28: , 2010), contained errors. In Table 3, the second-to-last column was labeled as Range, whereas it should have been labeled 95% CI. Also, in the row labeled Einhorn favorable prognosis, the total number of patients was originally given as 19 (Yes) and 88 (No). However, because none of the patients received a favorable prognosis, the data and the accompanying footnote for Einhorn favorable prognosis should have been omitted from the table. In Table A2, the second-to-last column was labeled as Range, whereas it should have been labeled 95% CI. Also, in the row labeled Einhorn favorable prognosis, the total number of patients was originally given as 17 (Yes) and 90 (No). However, because none of the patients received a favorable prognosis, the data and the accompanying footnote for Einhorn favorable prognosis should have been omitted from the table. In the Results section, under Prognostic Factor Analysis, the second-to-last sentence of the first paragraph was originally given as: Cisplatin sensitivity (P.52), Einhorn favorable prognosis (P.37), histology (seminoma v nonseminoma), and target carboplatin AUC did not have a significant impact on DFS. whereas it should have read: Cisplatin sensitivity (P.52), histology (seminoma v nonseminoma), and target carboplatin AUC did not have a significant impact on DFS. The online version has been corrected in departure from the print. Journal of Clinical Oncology and the authors apologize to readers for the mistakes. DOI: /JCO by American Society of Clinical Oncology
Manganese superoxide dismutase (MnSOD) gene polymorphism, interactions with carotenoid levels and prostate cancer risk
Carcinogenesis vol.29 no.12 pp.2335 2340, 2008 doi:10.1093/carcin/bgn212 Advance Access publication September 10, 2008 Manganese superoxide dismutase (MnSOD) gene polymorphism, interactions with carotenoid
More informationJ Clin Oncol 25: by American Society of Clinical Oncology INTRODUCTION
VOLUME 25 NUMBER 21 JULY 20 2007 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Prediction of Prostate Cancer for Patients Receiving Finasteride: Results From the Prostate Cancer Prevention Trial
More informationSelenium and Vitamin E Cancer Prevention Trial (SELECT): Questions and Answers. Key Points
CANCER FACTS N a t i o n a l C a n c e r I n s t i t u t e N a t i o n a l I n s t i t u t e s o f H e a l t h D e p a r t m e n t o f H e a l t h a n d H u m a n S e r v i c e s Selenium and Vitamin E
More informationThe Role of Observational Studies. Edward Giovannucci, MD, ScD Departments of Nutrition and Epidemiology
The Role of Observational Studies Edward Giovannucci, MD, ScD Departments of Nutrition and Epidemiology Disclosure Information As required, I would like to report that I have no financial relationships
More informationTrace Minerals and Heavy Metals: Implications in Prostate Cancer
REVIEW ARTICLE Trace Minerals and Heavy Metals: Implications in Prostate Cancer SIA Shah Dept of Surgery & Cancer, Faculty of Medicine, Imperial College London & NHS Hammersmith Hospital, London, United
More information[(Lung Cancer)] [Author: David J. Stewart] Published On (February, 2011) By David J. Stewart READ ONLINE
[(Lung Cancer)] [Author: David J. Stewart] Published On (February, 2011) By David J. Stewart READ ONLINE Eric Seitelman, 2 Perri Donenfeld, 1 Kevin Kay, 1 Kazuaki Takabe, 2 Shahriyour Andaz, 1 and Stewart
More informationBiomarkers: examples from cancer epidemiology
Biomarkers: examples from cancer epidemiology In memory of Sheila Bingham Tim Key Cancer Epidemiology Unit Nuffield Department of Clinical Medicine University of Oxford Sheila Bingham (Rodwell) 1947-2009
More informationNIH Public Access Author Manuscript World J Urol. Author manuscript; available in PMC 2012 February 1.
NIH Public Access Author Manuscript Published in final edited form as: World J Urol. 2011 February ; 29(1): 11 14. doi:10.1007/s00345-010-0625-4. Significance of preoperative PSA velocity in men with low
More informationSince the beginning of the prostate-specific antigen (PSA) era in the. Characteristics of Insignificant Clinical T1c Prostate Tumors
2001 Characteristics of Insignificant Clinical T1c Prostate Tumors A Contemporary Analysis Patrick J. Bastian, M.D. 1 Leslie A. Mangold, B.A., M.S. 1 Jonathan I. Epstein, M.D. 2 Alan W. Partin, M.D., Ph.D.
More informationPlasma insulin-like growth factor-1 and binding protein-3 and subsequent risk of prostate cancer in the PSA era q
Cancer Causes and Control (2005) 16:255 262 Ó Springer 2005 DOI 10.1007/s10552-004-3484-8 Plasma insulin-like growth factor-1 and binding protein-3 and subsequent risk of prostate cancer in the PSA era
More informationA review of phase III clinical trials of prostate cancer chemoprevention
The Royal College of Surgeons of England REVIEW doi 10.1308/003588407X179125 A review of phase III clinical trials of prostate cancer chemoprevention JF THORPE 1, S JAIN 1, TH MARCZYLO 2, AJ GESCHER 2,
More informationPROSTATE CANCER SCREENING: AN UPDATE
PROSTATE CANCER SCREENING: AN UPDATE William G. Nelson, M.D., Ph.D. Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins American Association for Cancer Research William G. Nelson, M.D., Ph.D. Disclosures
More informationIntroduction to REMARK: Reporting tumour marker prognostic studies
Introduction to REMARK: Reporting tumour marker prognostic studies Doug Altman The EQUATOR Network Centre for Statistics in Medicine, Oxford, UK C 1 S M Reliable research Reliability is determined by proper
More informationJ Clin Oncol 28: by American Society of Clinical Oncology INTRODUCTION
VOLUME 28 NUMBER 1 JANUARY 1 2010 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Clinical Results of Long-Term Follow-Up of a Large, Active Surveillance Cohort With Localized Prostate Cancer
More informationProstate Cancer: 2010 Guidelines Update
Prostate Cancer: 2010 Guidelines Update James L. Mohler, MD Chair, NCCN Prostate Cancer Panel Associate Director for Translational Research, Professor and Chair, Department of Urology, Roswell Park Cancer
More informationAssociation of C-peptide and leptin with prostate cancer incidence in the Health Professionals Follow-up Study
Cancer Causes Control (2014) 25:625 632 DOI 10.1007/s10552-014-0369-3 ORIGINAL PAPER Association of C-peptide and leptin with prostate cancer incidence in the Health Professionals Follow-up Study Gabriel
More informationPREVALENCE OF PROSTATE CANCER AMONG HYPOGONADAL MEN WITH PROSTATE-SPECIFIC ANTIGEN LEVELS OF 4.0 ng/ml OR LESS
ADULT UROLOGY PREVALENCE OF PROSTATE CANCER AMONG HYPOGONADAL MEN WITH PROSTATE-SPECIFIC ANTIGEN LEVELS OF 4.0 ng/ml OR LESS ABRAHAM MORGENTALER AND ERNANI LUIS RHODEN ABSTRACT Objectives. To determine
More informationSelenium status and risk of prostate cancer in a Danish population
Downloaded from orbit.dtu.dk on: Jul 23, 2018 Selenium status and risk of prostate cancer in a Danish population Outzen, Malene; Tjønneland, Anne; Larsen, Erik Huusfeldt; Friis, Søren ; Larsen, Signe B.;
More informationSelenium Supplementation and Prostate Cancer Mortality
JNCI J Natl Cancer Inst (2015) 107(1): dju360 doi:10.1093/jnci/dju360 First published online December 12, 2014 Article Selenium Supplementation and Prostate Cancer Mortality Stacey A. Kenfield, Erin L.
More informationSelenium and Vitamin E Cancer Prevention Trial (SELECT): Questions and Answers
1 FOR IMMEDIATE RELEASE: Monday, October 27, 2008 CONTACT: NCI Office of Media Relations (301) 496-6641 ncipressofficers@mail.nih.gov University of Michigan Nicole Fawcett (734) 764-2220 nfawcett@med.umich.edu
More informationPredictive Assays in Radiation Therapy
Outline Predictive Assays in Radiation Therapy Radiation Biology Introduction Early predictive assays Recent trends in predictive assays Examples for specific tumors Summary Lecture 4-23-2014 Introduction
More informationOMEGA CARO-E and the Lowering of the Risk for Cancer. Dr Carl Albrecht 28 February, 2013
OMEGA CARO-E and the Lowering of the Risk for Cancer Dr Carl Albrecht 28 February, 2013 Omega Caro E What is the link? The essence of Omega Caro-E Definitive Statement Accredited literature indicates that
More informationMendelian Randomization
Mendelian Randomization Drawback with observational studies Risk factor X Y Outcome Risk factor X? Y Outcome C (Unobserved) Confounders The power of genetics Intermediate phenotype (risk factor) Genetic
More informationSelection Bias in the Assessment of Gene-Environment Interaction in Case-Control Studies
American Journal of Epidemiology Copyright 2003 by the Johns Hopkins Bloomberg School of Public Health All rights reserved Vol. 158, No. 3 Printed in U.S.A. DOI: 10.1093/aje/kwg147 Selection Bias in the
More informationAlthough the test that measures total prostate-specific antigen (PSA) has been
ORIGINAL ARTICLE STEPHEN LIEBERMAN, MD Chief of Urology Kaiser Permanente Northwest Region Clackamas, OR Effective Clinical Practice. 1999;2:266 271 Can Percent Free Prostate-Specific Antigen Reduce the
More informationOVERVIEW OF GENE EXPRESSION-BASED TESTS IN EARLY BREAST CANCER
OVERVIEW OF GENE EXPRESSION-BASED TESTS IN EARLY BREAST CANCER Aleix Prat, MD PhD Medical Oncology Department Hospital Clínic of Barcelona University of Barcelona esmo.org Disclosures Advisory role for
More informationSystems Pathology in Prostate Cancer. Description
Section: Medicine Effective Date: July 15, 2015 Subject: Systems Pathology in Prostate Cancer Page: 1 of 8 Last Review Status/Date: June 2015 Systems Pathology in Prostate Cancer Description Systems pathology,
More informationSERUM SELENIUM AND THE RISK OF PROSTATE CANCER. A Research Project by. Chelsea Stancoff-Hon. Bachelor s of Science in Biology, Newman University, 2005
SERUM SELENIUM AND THE RISK OF PROSTATE CANCER A Research Project by Chelsea Stancoff-Hon Bachelor s of Science in Biology, Newman University, 2005 Submitted to the Department of Physician Assistant and
More informationHelping you make better-informed decisions 1-5
Helping you make better-informed decisions 1-5 The only test that provides an accurate assessment of prostate cancer aggressiveness A prognostic medicine product for prostate cancer. A common diagnosis
More informationManganese Superoxide Dismutase Polymorphism and Risk of Gastric Lesions, and Its Effects on Chemoprevention in a Chinese Population
Research Article Manganese Superoxide Dismutase Polymorphism and Risk of Gastric Lesions, and Its Effects on Chemoprevention in a Chinese Population Cancer Epidemiology, Biomarkers & Prevention Hua-kang
More informationPhase II Cancer Trials: When and How
Phase II Cancer Trials: When and How Course for New Investigators August 21-23, 2013 Acknowledgment Elizabeth Eisenhauer for some slides! Learning Objectives At the end of the session the participant should
More informationSystems Pathology in Prostate Cancer
Systems Pathology in Prostate Cancer Policy Number: 2.04.64 Last Review: 8/2014 Origination: 8/2010 Next Review: 8/2015 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will not provide coverage
More informationSelenium and Bladder Cancer Risk: a Meta-analysis
Published OnlineFirst on August 31, 2010 as 10.1158/1055-9965.EPI-10-0544 Research Article Selenium and Bladder Cancer Risk: a Meta-analysis Cancer Epidemiology, Biomarkers & Prevention André F.S. Amaral
More informationCHEMOPREVENTION OF HEAD AND NECK CANCER AND PROSTATE CANCER HUSEYIN ABALI, MD BASKENT UNIVERSITY MEDICAL ONCOLOGY ANKARA/TURKEY
CHEMOPREVENTION OF HEAD AND NECK CANCER AND PROSTATE CANCER HUSEYIN ABALI, MD BASKENT UNIVERSITY MEDICAL ONCOLOGY ANKARA/TURKEY Definition Cancer chemoprevention is defined as the use of natural, synthetic,
More informationPersonalized Therapy for Prostate Cancer due to Genetic Testings
Personalized Therapy for Prostate Cancer due to Genetic Testings Stephen J. Freedland, MD Professor of Urology Director, Center for Integrated Research on Cancer and Lifestyle Cedars-Sinai Medical Center
More informationSerum Retinol and Carotenoid Concentrations and Prostate Cancer Risk: Results from the Prostate Cancer Prevention Trial
Research Article Serum Retinol and Carotenoid Concentrations and Prostate Cancer Risk: Results from the Prostate Cancer Prevention Trial Sarah H. Nash 1, Cathee Till 2, Xiaoling Song 3, M. Scott Lucia
More informationCURRICULUM VITAE JASMEET K. GILL
CURRICULUM VITAE JASMEET K. GILL Department of Health Science California State University, Fullerton 800 N. State College Blvd. Fullerton, CA 92834 (657) 278-8657 Jasmeetgill@fullerton.edu EDUCATION: PhD
More informationNIH Public Access Author Manuscript Arch Dermatol. Author manuscript; available in PMC 2009 August 20.
NIH Public Access Author Manuscript Published in final edited form as: Arch Dermatol. 2009 August ; 145(8): 879 882. doi:10.1001/archdermatol.2009.176. Antioxidant Supplementation and Risk of Incident
More informationBlood a-tocopherol, c-tocopherol Levels and Risk of Prostate Cancer: A Meta-Analysis of Prospective Studies
Blood a-tocopherol, c-tocopherol Levels and Risk of Prostate Cancer: A Meta-Analysis of Prospective Studies Ran Cui., Zhu-Qing Liu., Qing Xu* Department of Medical Oncology, Shanghai Tenth People s Hospital,
More informationA prospective cohort study on intake of retinol, vitamins C and E, and carotenoids and prostate cancer risk (Netherlands)
Cancer Causes and Control 13: 573 582, 2002. 573 Ó 2002 Kluwer Academic Publishers. Printed in the Netherlands. A prospective cohort study on intake of retinol, vitamins C and E, and carotenoids and prostate
More informationAuthor's response to reviews
Author's response to reviews Title: Associations between toenail arsenic accumulation and dietary factors in a New Hampshire populationassociations between toenail arsenic accumulation and dietary factors
More informationThe Age-Related Eye Disease Study
What have the Age-Related Eye Disease Study (AREDS) and AREDS2 Taught Us? Emily Y. Chew, MD National Eye Institute/National Institutes of Health On Behalf of the AREDS and AREDS2 Research Groups Presenter
More informationElsevier Editorial System(tm) for European Urology Manuscript Draft
Elsevier Editorial System(tm) for European Urology Manuscript Draft Manuscript Number: EURUROL-D-13-00306 Title: Post-Prostatectomy Incontinence and Pelvic Floor Muscle Training: A Defining Problem Article
More informationNCCN Guidelines for Prostate V Meeting on 06/28/18
Guideline Page and Request PROS-2 through PROS-11 and PROS-D (pages 3 and 4). External request from GenomeDx Biosciences Request the NCCN Prostate Cancer Guidelines Panel to review the data in support
More informationUNIVERSITY OF CALIFORNIA, LOS ANGELES
UNIVERSITY OF CALIFORNIA, LOS ANGELES BERKELEY DAVIS IRVINE LOS ANGELES MERCED RIVERSIDE SAN DIEGO SAN FRANCISCO UCLA SANTA BARBARA SANTA CRUZ DEPARTMENT OF EPIDEMIOLOGY SCHOOL OF PUBLIC HEALTH CAMPUS
More informationAccelerating Innovation in Statistical Design
Implementing a National Cancer Clinical Trials System for the 21 st Century, Workshop #2 Session #5: Accelerating Innovation Through Effective Partnerships Accelerating Innovation in Statistical Design
More informationThe cost of prostate cancer chemoprevention: a decision analysis model Svatek R S, Lee J J, Roehrborn C G, Lippman S M, Lotan Y
The cost of prostate cancer chemoprevention: a decision analysis model Svatek R S, Lee J J, Roehrborn C G, Lippman S M, Lotan Y Record Status This is a critical abstract of an economic evaluation that
More informationIntroduction to Clinical Trials - Day 1 Session 2 - Screening Studies
Introduction to Clinical Trials - Day 1 Session 2 - Screening Studies Presented July 23, 2018 Susanne J. May Department of Biostatistics University of Washington Daniel L. Gillen Department of Statistics
More informationOral Selenium Supplementation Has No Effect on Prostate- Specific Antigen Velocity in Men Undergoing Active Surveillance for Localized Prostate Cancer
Published OnlineFirst on July 20, 2010 as 10.1158/1940-6207.CAPR-09-0143 Research Article Oral Selenium Supplementation Has No Effect on Prostate- Specific Antigen Velocity in Men Undergoing Active Surveillance
More informationTitle: Synuclein Gamma Predicts Poor Clinical Outcome in Colon Cancer with Normal Levels of Carcinoembryonic Antigen
Author's response to reviews Title: Synuclein Gamma Predicts Poor Clinical Outcome in Colon Cancer with Normal Levels of Carcinoembryonic Antigen Authors: Caiyun Liu (liucaiyun23@yahoo.com.cn) Bin Dong
More informationComparison of Futility Monitoring Methods Using RTOG Clinical Trials. Q. Ed Zhang, PhD
Comparison of Futility Monitoring Methods Using RTOG Clinical Trials Q. Ed Zhang, PhD 1 Futility Monitoring Definition: Monitoring for early determination that trial results will not be in favor of H 1
More informationCONTEMPORARY UPDATE OF PROSTATE CANCER STAGING NOMOGRAMS (PARTIN TABLES) FOR THE NEW MILLENNIUM
RAPID COMMUNICATION CME ARTICLE CONTEMPORARY UPDATE OF PROSTATE CANCER STAGING NOMOGRAMS (PARTIN TABLES) FOR THE NEW MILLENNIUM ALAN W. PARTIN, LESLIE A. MANGOLD, DANA M. LAMM, PATRICK C. WALSH, JONATHAN
More informationSignificance of Serum Testosterone for Prostate-Specific Antigen (PSA) Elevation and Prediction of Prostate Cancer in Patients with PSA Above 10 ng/ml
www.kjurology.org DOI:10.111/kju.010.51.1.81 Urological Oncology Significance of Serum Testosterone for Prostate-Specific Antigen (PSA) Elevation and Prediction of Prostate Cancer in Patients with PSA
More informationFinasteride Does Not Increase the Risk of High-grade Prostate Cancer: A Biasadjusted. Mary W. Redman, Ph.D. 1. Catherine M. Tangen, Dr.
Finasteride Does Not Increase the Risk of High-grade Prostate Cancer: A Biasadjusted Modeling Approach Mary W. Redman, Ph.D. 1 Catherine M. Tangen, Dr. PH 1 Phyllis J. Goodman, MS 1 Howard Parnes, M.D.
More informationWhat Can Randomized Controlled Trials Tell Us About Nutrition and Cancer Prevention?
What Can Randomized Controlled Trials Tell Us About Nutrition and Cancer Prevention? Tim Byers, MD, MPH Abstract Randomized controlled trials are regarded as the most definitive of study designs. The randomized
More informationDo the sample size assumptions for a trial. addressing the following question: Among couples with unexplained infertility does
Exercise 4 Do the sample size assumptions for a trial addressing the following question: Among couples with unexplained infertility does a program of up to three IVF cycles compared with up to three FSH
More informationHPV INDUCED OROPHARYNGEAL CARCINOMA radiation-oncologist point of view. Prof. dr. Sandra Nuyts Dep. Radiation-Oncology UH Leuven Belgium
HPV INDUCED OROPHARYNGEAL CARCINOMA radiation-oncologist point of view Prof. dr. Sandra Nuyts Dep. Radiation-Oncology UH Leuven Belgium DISCLOSURE OF INTEREST Nothing to declare HEAD AND NECK CANCER -HPV
More informationSession 4 Chemotherapy for castration refractory prostate cancer First and second- line chemotherapy
Session 4 Chemotherapy for castration refractory prostate cancer First and second- line chemotherapy October- 2015 ESMO 2004 October- 2015 Fyraftensmøde 2 2010 October- 2015 Fyraftensmøde 3 SWOG 9916 OS
More informationProstate-Specific Antigen Testing of Older Men
Prostate-Specific Antigen Testing of Older Men H. Ballentine Carter, Patricia K. Landis, E. Jeffrey Metter, Lee A. Fleisher, Jay D. Pearson Background: Elevated serum prostate-specific antigen (PSA) levels
More informationGenetic Predictors of Radiosensitivity.
Genetic Predictors of Radiosensitivity. Richard G. Stock, MD Professor, Director of Genito-Urinary Oncology Department of Radiation Oncology Ichan School of Medicine at Mount Sinai New York, NY DISCLOSURE
More informationPrevalence and Risk Factors For Lower Selenium Status Among Adult White Males in the USA
Prevalence and Risk Factors For Lower Selenium Status Among Adult White Males in the USA Andrew Pinfold 1 Abstract Objectives: To establish the prevalence of lower serum selenium status (
More informationDiabetes and Risk of Prostate Cancer in a Prospective Cohort of US Men
American Journal of Epidemiology Copyright 2005 by the Johns Hopkins Bloomberg School of Public Health All rights reserved Vol. 161, No. 2 Printed in U.S.A. DOI: 10.1093/aje/kwh334 Diabetes and Risk of
More informationRALPH MUECKE 1,8, THEODOR KLOTZ 2, JOSEF GIEDL 3, JENS BUENTZEL 4,8, GUENTHER KUNDT 5, KLAUS KISTERS 6,8, FRANZ-JOSEF PROTT 1 & OLIVER MICKE 7,8
Acta Oncologica, 29; 48: 452456 ORIGINAL ARTICLE Whole blood selenium levels (WBSL) in patients with prostate cancer (PC), benign prostatic hyperplasia (BPH) and healthy male inhabitants (HMI) and prostatic
More informationPhysical activity, Obesity, Diet and Colorectal Cancer Prognosis. Jeffrey Meyerhardt, MD, MPH Dana-Farber Cancer Institute Boston, MA
Physical activity, Obesity, Diet and Colorectal Cancer Prognosis Jeffrey Meyerhardt, MD, MPH Dana-Farber Cancer Institute Boston, MA Colorectal Cancer Incidence ~148,000 cases in US annually and ~50,000
More informationTESTOSTERONE REPLACEMENT THERAPY. WHAT IS THE REAL RISK? WHAT TO DO IN PROSTATE CANCER?
TESTOSTERONE REPLACEMENT THERAPY. WHAT IS THE REAL RISK? WHAT TO DO IN PROSTATE CANCER? TESTOSTERONE REPLACEMENT THERAPY (TRT) Nuno Tomada, MD, PhD Department of Urology of Hospital S. João Faculty of
More informationAT Hickerson 1, GT Clifton 1, DF Hale 1, KM Peace 1, JP Holmes 2, TJ Vreeland 3, JK Litton 4, RK Murthy 4, KK Lukas 5, EA Mittendorf 6, GE Peoples 7
Final analysis of Nelipepimut-S plus GM-CSF with trastuzumab versus GM-CSF with trastuzumab to prevent recurrences in high-risk, HER2 low-expressing breast cancer: a prospective, randomized, blinded multicenter
More informationWhen PSA fails. Urology Grand Rounds Alexandra Perks. Rising PSA after Radical Prostatectomy
When PSA fails Urology Grand Rounds Alexandra Perks Rising PSA after Radical Prostatectomy Issues Natural History Local vs Metastatic Treatment options 1 10 000 men / year in Canada 4000 RRP 15-year PSA
More informationRisk factors for prostate cancer incidence and progression in the health professionals follow-up study
Int. J. Cancer: 121, 1571 1578 (2007) ' 2007 Wiley-Liss, Inc. Risk factors for prostate cancer incidence and progression in the health professionals follow-up study Edward Giovannucci 1,2,3 *, Yan Liu
More informationFAST TRACK Antioxidant vitamin and mineral supplementation and prostate cancer prevention in the SU.VI.MAX trial
Int. J. Cancer: 116, 182 186 (2005) ' 2005 Wiley-Liss, Inc. FAST TRACK Antioxidant vitamin and mineral supplementation and prostate cancer prevention in the SU.VI.MAX trial François Meyer 1 *, Pilar Galan
More informationProstate Cancer Incidence
Prostate Cancer: Prevention, Screening and Treatment Philip Kantoff MD Dana-Farber Cancer Institute Professor of fmedicine i Harvard Medical School Prostate Cancer Incidence # of patients 350,000 New Cases
More informationFat, Fiber, Meat and the Risk of Colorectal Adenomas
American Journal of Gastroenterology ISSN 0002-9270 C 2005 by Am. Coll. of Gastroenterology doi: 10.1111/j.1572-0241.2005.00336.x Published by Blackwell Publishing Fat, Fiber, Meat and the Risk of Colorectal
More informationCANCER EPIDEMIOLOGY AND PATHOGENESIS (EPID 770) FALL 2009
CANCER EPIDEMIOLOGY AND PATHOGENESIS (EPID 770) FALL 2009 Tues/Thurs 12:30 1:45, McGavran Greenberg 1304 Instructor: Office: Melissa Troester, Ph.D., M.P.H. 2104H McGavran Greenberg Phone: (919) 966 7408
More informationPhase II Cancer Trials: When and How
Phase II Cancer Trials: When and How Course for New Investigators August 9-12, 2011 Learning Objectives At the end of the session the participant should be able to Define the objectives of screening vs.
More informationInformation Content of Five Nomograms for Outcomes in Prostate Cancer
Anatomic Pathology / NOMOGRAMS IN PROSTATE CANCER Information Content of Five Nomograms for Outcomes in Prostate Cancer Tarek A. Bismar, MD, 1 Peter Humphrey, MD, 2 and Robin T. Vollmer, MD 3 Key Words:
More informationStatus of selenium in prostate cancer prevention
British Journal of Cancer (2004) 91, 195 199 All rights reserved 0007 0920/04 $30.00 www.bjcancer.com Minireview Status of selenium in prostate cancer prevention Jr*,1 1 Center Director, Grand Forks Human
More informationEpidemiological evidence linking food, nutrition, physical activity and prostate cancer risk: results from the Continuous Update Project
Epidemiological evidence linking food, nutrition, physical activity and prostate cancer risk: results from the Continuous Update Project World Cancer Congress, Saturday 6 December 2014 Michael Leitzmann
More informationreceive adjuvant chemotherapy
Women with high h risk early stage endometrial cancer should receive adjuvant chemotherapy Michael Friedlander The Prince of Wales Cancer Centre and Royal Hospital for Women The Prince of Wales Cancer
More informationMedical Policy Manual. Topic: Systems Pathology in Prostate Cancer Date of Origin: December 30, 2010
Medical Policy Manual Topic: Systems Pathology in Prostate Cancer Date of Origin: December 30, 2010 Section: Laboratory Last Reviewed Date: April 2014 Policy No: 61 Effective Date: July 1, 2014 IMPORTANT
More informationObservational Studies vs. Randomized Controlled Trials
Observational Studies vs. Randomized Controlled Trials Edward Giovannucci, MD, ScD Harvard School of Public Health Harvard Medical School Boston MA 02115 (1)The relevance of observational data as compared
More informationPCa Commentary. Executive Summary: The "PCa risk increased directly with increasing phi values."
1101 Madison Street Suite 1101 Seattle, WA 98104 P 206-215-2490 www.seattleprostate.com PCa Commentary Volume 77 September October 2012 CONTENT Page The Prostate 1 Health Index Active Surveillance 2 A
More informationbreast cancer; relative risk; risk factor; standard deviation; strength of association
American Journal of Epidemiology The Author 2015. Published by Oxford University Press on behalf of the Johns Hopkins Bloomberg School of Public Health. All rights reserved. For permissions, please e-mail:
More informationPrecision Chemoprevention with Aspirin
Precision Chemoprevention with Aspirin Andrew T. Chan, MD, MPH Clinical and Translational Epidemiology Unit Division of Gastroenterology Massachusetts General Hospital February 3-5, 2016 Lansdowne Resort,
More informationA Personal History NIH CWRU U of TN U of Miami Animal Model for Bladder Cancer Carcinogen induced FANFT Three Models Primary tumors individual tumors, simulates clinical scenario of locally advanced cancer
More informationA Practical Guide to Active Surveillance for Prostate Cancer. J. Kellogg Parsons, MD, MHS, FACS
A Practical Guide to Active Surveillance for Prostate Cancer J. Kellogg Parsons, MD, MHS, FACS Associate Professor, Department of Urology, Division of Urologic Oncology, Moores UCSD Comprehensive Cancer
More information(2015) : 85 (5) ISSN
Boniol, Mathieu and Autier, Philippe and Perrin, Paul and Boyle, Peter (2015) Variation of prostate-specific antigen value in men and risk of high-grade prostate vancer : analysis of the prostate, lung,
More informationSupplemental Digital Content-Table 1. Quality assessment of included case-control studies Selection Comparability Exposure
Supplemental Digital Content-Table 1. Quality assessment of included case-control studies Selection Comparability Exposure Is the case Representativen Selection of Definition of Comparability of cases
More informationLessons learned for the conduct of a successful screening trial
Lessons learned for the conduct of a successful screening trial Christine D. Berg, M.D. Adjunct Professor Department of Radiation Oncology Johns Hopkins Medicine IOM State of the Science in Ovarian Cancer
More informationMeasurement of Fruit and Vegetable Consumption with Diet Questionnaires and Implications for Analyses and Interpretation
American Journal of Epidemiology Copyright ª 2005 by the Johns Hopkins Bloomberg School of Public Health All rights reserved Vol. 161, No. 10 Printed in U.S.A. DOI: 10.1093/aje/kwi115 Measurement of Fruit
More informationAssociation of Plasma Micronutrient Levels and Urinary Isoprostane with Risk of Lung Cancer: The Multiethnic Cohort Study
1962 Association of Plasma Micronutrient Levels and Urinary Isoprostane with Risk of Lung Cancer: The Multiethnic Cohort Study Meira Epplein, 1 Adrian A. Franke, 1 Robert V. Cooney, 1 J. Steven Morris,
More informationPresentation with lymphadenopathy
Presentation with lymphadenopathy Theo M. de Reijke MD PhD FEBU Department of Urology Academic Medical Center Amsterdam Rationale for RRP in N+ disease Prevention local problems Better survival in limited
More informationNutrition and gastrointestinal cancer: An update of the epidemiological evidence
Nutrition and gastrointestinal cancer: An update of the epidemiological evidence Krasimira Aleksandrova, PhD MPH Nutrition, Immunity and Metabolsim Start-up Lab Department of Epidemiology German Institute
More informationHormones and Healthy Bones Joint Project of National Osteoporosis Foundation and Association of Reproductive Health Professionals
Hormones and Healthy Bones Joint Project of National Osteoporosis Foundation and Association of Reproductive Health Professionals Literature Review (January 2009) Hormone Therapy for Women Women's Health
More informationLinks in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website. Jurisdiction Oregon. Retirement Date N/A
Local Coverage Determination (LCD): Circulating Tumor Cell Marker Assays (L35096) Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website. Contractor Information
More informationAndrogen deprivation therapy for treatment of localized prostate cancer and risk of
Androgen deprivation therapy for treatment of localized prostate cancer and risk of second primary malignancies Lauren P. Wallner, Renyi Wang, Steven J. Jacobsen, Reina Haque Department of Research and
More informationThe Making of the Fittest: Natural Selection in Humans
INTRODUCTION MENDELIAN GENETICS, PROBABILITY, PEDIGREES, AND CHI-SQUARE STATISTICS Hemoglobin is a protein found in red blood cells (RBCs) that transports oxygen throughout the body. The hemoglobin protein
More informationJ Clin Oncol by American Society of Clinical Oncology INTRODUCTION
JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Long-Term, Supplemental, One-Carbon Metabolism Related Vitamin B Use in Relation to Risk in the Vitamins and Lifestyle (VITAL) Cohort Theodore M.
More informationThe Breast Cancer Family Registry: Description of Resource and some Applications
The Breast Cancer Family Registry: Description of Resource and some Applications Mary Beth Terry, PhD Associate Professor Department of Epidemiology Mailman School of Public Health Overview of Talk Description
More informationEmerging Approaches for (Neo)Adjuvant Therapy for ER+ Breast Cancer
Emerging Approaches for (Neo)Adjuvant Therapy for E+ Breast Cancer Cynthia X. Ma, M.D., Ph.D. Associate Professor of Medicine Washington University in St. Louis Outline Current status of adjuvant endocrine
More informationA meta-analysis of individual participant data reveals an association between circulating levels of IGF-I and prostate cancer risk
Supplementary Materials and Methods A meta-analysis of individual participant data reveals an association between circulating levels of IGF-I and prostate cancer risk Correspondence to: Ruth C. Travis
More informationSerum 25-OH vitamin D levels and risk of developing prostate cancer in older men
DOI 10.1007/s10552-010-9557-y ORIGINAL PAPER Serum 25-OH vitamin D levels and risk of developing prostate cancer in older men Christine M. Barnett Carrie M. Nielson Jackie Shannon June M. Chan James M.
More information